Building-The-Next-Generation-of-Bioprocessing-Capability

This panel discussion from the Danaher Summit 2026 brings together Dan Bracewell (UCL), Steve Bates (UK government life sciences policy), and Alistair (Faculty AI) to examine whether the bioprocessing workforce can keep pace with accelerating scientific and technological change. Cytiva's Global Biopharma Index data shows 38% of respondents face critical or severe talent shortages in novel modality roles and 29% in digital and AI skills. The panel identifies T-shaped skills, continuous capability investment, regulatory science capacity, and role-specific AI deployment as key levers to avoid a workforce bottleneck. The discussion spans academia, government, and industry perspectives on what systemic changes are needed within the next 24 months to support the next era of bioprocessing.

Key Takeaways

Cytiva's 2026 Global Biopharma Index shows 38% of industry respondents face critical or severe talent shortages for novel drug modality roles, and 29% for digital and AI roles, with all shortage categories increasing.
Workforce readiness is now a critical bottleneck in bioprocessing with stakes spanning national competitiveness, supply chain resilience, manufacturing capacity, and speed of patient access to new therapies.
T-shaped skills are the new baseline: technology is breaking down disciplinary silos and requiring bioprocessing professionals to understand upstream and downstream processes beyond their core specialty.
Continuous capability investment is essential — one-time training events such as a Python course are insufficient; organizations must treat skill development as an ongoing commitment that evolves with technology.
AI could redefine the scientist's role if it moves from automating monitoring to generating experimental hypotheses, but life science AI still requires large volumes of specialized biological data that cannot be scraped from the internet.
The most important near-term change is replacing generic bundled AI tools with role-specific AI aligned to department and business strategy; success should be measured by cognitive load reduction, not engagement surveys.
Regulatory science is a uniquely government-funded function: investing in MHRA and equivalent regulatory capacity is essential to allow novel bioprocessing processes to reach patients in any market.
UCL's 20-year MBI industry-facing program demonstrates that sustained university-industry partnership is feasible, but course approval processes and staff availability remain barriers to rapid curriculum adaptation.